Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study

NCT06783127 is registered in ClinicalTrials.gov with Santa Chiara Hospital as lead sponsor.

NCT NCT06783127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06783127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
Lead sponsor
Santa Chiara Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2023
Completion date
December 31, 2026
Enrollment
3,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brca mutation, castrate resistant prostate cancer, prostate cancer